SoftBank Shares Slide as Oracle’s AI Spending Plans Fuel Market Jitters 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
Microsoft Unveils Massive Global AI Investments, Prioritizing India’s Rapidly Growing Digital Market 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
AstraZeneca (NASDAQ: AZN) has unveiled plans to invest $50 billion in U.S. manufacturing and R&D infrastructure by 2030, marking one of the largest expansions in the pharmaceutical industry. The move responds to renewed pressure from President Donald Trump’s administration to localize drug production and reduce reliance on imports.
The Anglo-Swedish drugmaker will build a new manufacturing plant in Virginia focused on active ingredients for weight-loss drugs, including a GLP-1 candidate and an oral PCSK9 inhibitor. It also plans to expand operations in Maryland, Massachusetts, California, Indiana, and Texas, enhancing its R&D capabilities and clinical trial supply chain.
CEO Pascal Soriot announced the investment in Washington, citing the need for global pricing reform. “The U.S. cannot shoulder the world’s R&D costs alone,” he said, calling for other nations to pay more for drugs.
Over 40% of AstraZeneca’s 2024 revenue came from the U.S., the world’s largest pharmaceutical market valued at $635 billion. The company aims to hit $80 billion in annual revenue by 2030, with half coming from the U.S.
The $50 billion pledge follows Trump’s threats of pharmaceutical tariffs, with a possible grace period of 12–18 months. U.S. Commerce Secretary Howard Lutnick emphasized the administration’s goal to end foreign dependency in the drug supply chain.
The investment is in addition to a $3.5 billion commitment made in November 2024. It mirrors a similar $50 billion pledge by Roche and aligns with major expansion plans from Eli Lilly, Johnson & Johnson, Novartis, and Sanofi.
AstraZeneca employs about 18,000 people in the U.S. and hinted at creating tens of thousands of new jobs, though exact figures were not disclosed. The company declined to comment on rumors of a potential U.S. stock market listing shift.
